Government-Owned Inventions; Availability for Licensing
| Published date | 22 February 2023 |
| Record Number | 2023-03595 |
| Citation | 88 FR 10906 |
| Court | National Institutes Of Health |
| Section | Notices |
10906
Federal Register / Vol. 88, No. 35 / Wednesday, February 22, 2023 / Notices
stem cell transplantation and donation.
The ACBSCT may also review the state
of the science using adult stem cells and
birthing tissues to develop new types of
therapies for patients, for the purpose of
considering the potential inclusion of
such new types of therapies in the C.W.
Bill Young Cell Transplantation
Program.
The recharter for ACBSCT was
approved on February 15, 2023.
Recharter of the ACBSCT charter gives
authorization for the ACBSCT to operate
until February 19, 2025.
A copy of the ACBSCT charter is
available on the ACBSCT website at
https://bloodstemcell.hrsa.gov/about/
advisory-council. A copy of the charter
can also be obtained by accessing the
FACA database that is maintained by
the Committee Management Secretariat
under the General Services
Administration. The website address for
the FACA database is http://
www.facadatabase.gov/.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023–03604 Filed 2–21–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, PAR–
19–367: Maximizing Investigators’
Research Award, February 23–24, 2023,
10:00 a.m. to 8:00 p.m., National
Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting), which was published
in the Federal Register on January 31,
2023, 88 FR 6288, Doc 2023–01953.
This meeting is being amended to
change the panel name to ‘‘PAR–20–
117: Maximizing Investigators’ Research
Award for Early-Stage Investigators’’.
The meeting is closed to the public.
Dated: February 15, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03572 Filed 2–21–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Healthcare
Inequities in ADRD.
Date: March 14, 2023.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Sandhya Sanghi, Ph.D.,
Scientific Review Officer, National Institutes
of Health, National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
(2N230) NIA/SRB, Bethesda, MD 20892,
(301) 496–2879, sandhya.sanghi@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: February 15, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03645 Filed 2–21–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health
and Health Disparities; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; John Lewis NIMHD
Research Endowment Program.
Date: March 22, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIMHD DEM II, Suite 800, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Xinli Nan, M.D., Ph.D.,
Scientific Review Officer, Office of
Extramural Research Activities, National
Institute on Minority Health and Health
Disparities, National Institutes of Health,
6707 Democracy Boulevard, Suite 800,
Bethesda, MD 20892, (301) 594–7784,
Xinli.Nan@nih.gov.
Dated: February 15, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03571 Filed 2–21–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY
: National Institutes of Health,
HHS.
ACTION
: Notice.
SUMMARY
: The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT
: Dr.
Maryann Puglielli at (240)–627–3723, or
maryann.puglielli@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301–496–
VerDate Sep<11>2014 19:42 Feb 21, 2023 Jkt 259001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\22FEN1.SGM 22FEN1
lotter on DSK11XQN23PROD with NOTICES1
10907
Federal Register / Vol. 88, No. 35 / Wednesday, February 22, 2023 / Notices
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION
:
Technology description follows:
Replicating RNA Vaccine for Crimean-
Congo Hemorrhagic Fever Virus
Description of Technology:
Crimean-Congo hemorrhagic fever
(CCHF) is a deadly hemorrhagic fever
having a high mortality rate. The disease
results from infection of an individual
by Crimean-Congo hemorrhagic fever
virus (CCHFV), which is a tick-borne
bunyavirus endemic in Southern and
Eastern Europe, Africa, the Middle East,
and Asia. Geographically, case
distribution is consistent with the range
of Hyalomma genus ticks, the main
reservoir of CCHFV, and is likely to
expand due to climate change. Humans
may be infected from tick bites, through
contact with infected animals or animal
tissue. Nosocomial human-to-human
transmission has also been described
primarily for healthcare workers. Initial
symptoms of CCHF include acute onset
of a non-specific febrile illness
consisting of sudden fever, myalgia,
diarrhea, nausea, and vomiting. The
hemorrhagic phase is characterized by
large areas of severe bruising and
uncontrolled bleeding throughout the
body; among hospitalized patients, case
fatality rates have ranged from 9–50%.
Currently, there is no approved specific
antiviral or vaccine for CCHFV
infection.
Scientists at NIAID in collaboration
with HDT Bio have developed a
replicating RNA (repRNA) vaccine
based on Venezuelan Equine
Encephalitis Virus replicon RNA
expressing either the nucleoprotein
(repNP) or the glycoprotein precursor
(repGPC) from CCHFV alone or in
combination. In mice, the repNP
vaccine primarily elicited a robust but
non-neutralizing antibody response
while repGPC elicited primarily cellular
immunity against epitopes in the
CCHFV NSm and Gc proteins.
Vaccination with repNP or repNP +
repGPC resulted in protection against
challenge with a heterologous strain of
CCHFV in mice.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
•Prophylactic usage against CCHFV
infections in normal or high-risk
populations.
•Therapeutic treatment, alone or in
combination, in patients with CCHFV
infection.
•Assay development for
surveillance, diagnostic, and prevention
measures.
Competitive Advantages:
•Uses a cell-free system to express
antigens thereby increasing safety of the
vaccine.
•RepRNA as a platform can drive
high-level protein expression and
mimics viral replication in a single
round of replication resulting in a more
robust immune response in comparison
to DNA and mRNA platforms.
Development Stage: Pre-clinical.
Inventors: Heinz Feldmann (NIAID);
David Hawman, (NIAID); and Jesse
Erasmus (HDT Bio).
Publications: Leventhal, S. et al.,
‘‘Replicating RNA Vaccination Elicits an
Unexpected Immune Response that
Efficiently Protects Mice Against Lethal
Crimean-Congo Hemorrhagic Fever
Virus Challenge’’, EBioMedicine
82:104188 (2022).
Intellectual Property: U.S. provisional
patent application 63/365,015 filed May
19, 2022.
Licensing Contact: To license this
technology, please contact Dr. Maryann
Puglielli at (240)–627–3723, or
maryann.puglielli@nih.gov, and
reference E–103–2022.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact Dr. Maryann Puglielli at (240)–
627–3723, or maryann.puglielli@
nih.gov.
Dated: February 8, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–03595 Filed 2–21–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Specialized
Centers of Research Excellence (SCORE) on
Sex Differences.
Date: March 21–22, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elaine Sierra-Rivera, Ph.D.,
IRG Chief, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 6182, Bethesda, MD 20892,
(301) 435–2514, riverase@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Fertility
Status as a Marker for Overall Health.
Date: March 21, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anthony Wing Sang Chan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 809K,
Bethesda, MD 20892, (301) 496–9392,
chana3@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Endocrine and Metabolic
Systems.
Date: March 23, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victoria Martinez Virador,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–4703, victoria.virador@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cancer
Diagnostics and Treatments (CDT).
Date: March 23–24, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Marriott Georgetown,
1221 22nd Street NW, Washington, DC
20037.
Contact Person: Victor A. Panchenko,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 802B2,
VerDate Sep<11>2014 19:42 Feb 21, 2023 Jkt 259001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\22FEN1.SGM 22FEN1
lotter on DSK11XQN23PROD with NOTICES1
